KALA BIO Inc (KALA)

[MDizzle]

Kala Pharmaceuticals announced the launch of EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease


7:03 AM ET 1/7/21 | Briefing.com
EYSUVIS is now available in national and regional U.S. pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or through home delivery.
Kala has completed the hiring and onboarding of its expanded ophthalmology sales force, which now consists of 91 sales professionals calling on eyecare professionals, including ophthalmologists and optometrists. The Company plans to expand its sales force to approximately 125 sales representatives in 2021, pending the status of the COVID-19 pandemic.